TrialThoracic cancer2018

Combination TS-1 plus EGFR-tyrosine kinase inhibitors (TKIs) for the treatment of non-small cell lung cancer after progression on first-line or further EGFR-TKIs: A phase II, single-arm trial.

Lu Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.